ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Carmell Corporation

Carmell Corporation (CTCX)

0.325
-0.0072
( -2.17% )
Updated: 15:22:13

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.325
Bid
0.3204
Ask
0.3299
Volume
100,952
0.32 Day's Range 0.336351
0.29 52 Week Range 4.3128
Market Cap
Previous Close
0.3322
Open
0.3322
Last Trade
7
@
0.3204
Last Trade Time
15:23:40
Financial Volume
$ 32,724
VWAP
0.324156
Average Volume (3m)
4,985,225
Shares Outstanding
20,905,407
Dividend Yield
-
PE Ratio
-0.41
Earnings Per Share (EPS)
-0.77
Revenue
-
Net Profit
-16.12M

About Carmell Corporation

Carmell Corporation (CTCX) is a bio-aesthetics company that utilizes the Carmell SecretomeTM to support skin and hair health. The Carmell SecretomeTM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-... Carmell Corporation (CTCX) is a bio-aesthetics company that utilizes the Carmell SecretomeTM to support skin and hair health. The Carmell SecretomeTM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, Carmell has extensively tested the technology underpinning the Carmell SecretomeTM. In addition, Carmell has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul FourteenTM, which are 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell's microemulsion formulations do not utilize mineral or vegetable oils across its entire product line and are designed to be non-comedogenic. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Carmell Corporation is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CTCX. The last closing price for Carmell was $0.33. Over the last year, Carmell shares have traded in a share price range of $ 0.29 to $ 4.3128.

Carmell currently has 20,905,407 shares outstanding. The market capitalization of Carmell is $6.94 million. Carmell has a price to earnings ratio (PE ratio) of -0.41.

CTCX Latest News

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Company” or “Carmell”), today announced the...

Carmell Announces Successful Closing of $3.0 Million Private Placement

PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Announces $3.0 Million Private Placement

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced it will...

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.024-6.876790830950.3490.37990.3125694710.34419673CS
4-0.028-7.932011331440.3531.270.3022145455420.57216592CS
12-0.675-67.511.270.2949852250.57125757CS
26-1.705-83.99014778332.032.930.2923061510.57541055CS
52-1.655-83.58585858591.984.31280.2911753780.58362789CS
156-7.375-95.77922077927.713.0510.299847350.89110854CS
260-7.375-95.77922077927.713.0510.299847350.89110854CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 5.38
(169.00%)
62.52M
CDXCChromaDex Corporation
$ 5.595
(60.32%)
34.41M
ATHAAthira Pharma Inc
$ 0.64
(49.50%)
231.62M
NMHINatures Miracle Holding Inc
$ 0.135697
(37.62%)
26.63M
ICCTiCoreConnect Inc
$ 0.2153
(35.41%)
89.69M
EPIXESSA Pharma Inc
$ 1.565
(-69.90%)
30.6M
ELABElevai Labs Inc
$ 0.0301
(-48.98%)
174.21M
OSTOstin Technology Group Company Ltd
$ 0.31
(-38.00%)
2.07M
LXRXLexicon Pharmaceuticals Inc
$ 1.215
(-37.69%)
19.03M
GOEVCanoo Inc
$ 0.542
(-28.40%)
13.53M
ATHAAthira Pharma Inc
$ 0.6409
(49.71%)
228.06M
SQQQProShares UltraPro Short QQQ
$ 7.41
(-2.50%)
194.18M
ELABElevai Labs Inc
$ 0.0301
(-48.98%)
173.53M
NVDANVIDIA Corporation
$ 135.8067
(2.29%)
160.63M
INTCIntel Corporation
$ 23.2992
(8.27%)
140.62M

CTCX Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
CTCX..............................https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 weeks ago
.56 + 16% Run run another pump whoops might be too late lol
👍️0
Invest-in-America Invest-in-America 2 weeks ago
CTCX: And STILL under $2.00.

_____________________________________________________________________
I'm producing a film, "American Cars of 1908" --- tap link below for latest edition:
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExOXVyb2N1NXVkejE5em04cDMyYnRvbDV2ejAzeHdsdmZzc2JxajQwZSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/f1NTdkdbG4XzW/giphy.gif
👍️0
glenn1919 glenn1919 2 weeks ago
CTCX...................................https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 2 weeks ago
Oh cmon
👍️0
frans frans 3 weeks ago
CTCX 0.53 X 0.53
👍️0
tw0122 tw0122 3 weeks ago
Ok .50 now
👍️0
Monksdream Monksdream 3 months ago
CTCX under $2
👍️0
Monksdream Monksdream 4 months ago
CTCX under $2
👍️0
stock1ace1 stock1ace1 1 year ago
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

https://www.businesswire.com/news/home/20230809916251/en/Carmell-Announces-Successful-Closing-of-Merger-with-Axolotl-Biologix-and-Launch-of-a-New-Brand-Identity
👍️0
stock1ace1 stock1ace1 1 year ago
CTCX $2.90 #merger complete rsi 22 oversold macd crossover bullish

https://stockcharts.com/h-sc/ui?s=Ctcx
👍️0
AJ Freely AJ Freely 1 year ago
$CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Up 57% Pre-Market/ Current Price $4.74
👍️0
Monksdream Monksdream 1 year ago
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
👍️0

Your Recent History

Delayed Upgrade Clock